You are invited to a benefit dinner to heal trauma through MDMA therapy in Boulder, Colorado, on Thursday, January 25, 2018.

Celebrate the launch of our new research site in Boulder, Colorado, where MDMA-assisted psychotherapy will be investigated as a treatment for posttraumatic stress disorder (PTSD) in a Phase 3 clinical trial.

Reserve your seat today to join the company of like-minded individuals, enjoy a 3-course meal, and contribute to this vital and promising movement.

Purchase tickets: maps.org/boulder2018

MAPS Founder and Executive Director, Rick Doblin, Ph.D., will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines, as valuable tools for inspiring creativity, for personal and spiritual growth, and for catalyzing resolutions to global and social conflicts.

Leading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).

—

Breakthrough Therapy Designation:

Preliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials, the final phase of research, as efficiently as possible.

Phase 3 trials require more clinical sites, more therapists, more patients, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics.

—

Healing Trauma:

There is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies, we can work together toward healing millions of people suffering from PTSD.

We can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs.

—

Speakers:

MAPS Founder and Executive Director Rick Doblin, Ph.D., has a professional goal to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.

Marcela Ot’alora, M.A., L.P.C., is a psychotherapist and an artist working in Boulder, Colorado. Marcela worked as a co-therapist in MAPS’ first government-approved MDMA-assisted psychotherapy study in Madrid, Spain, served as the Principal Investigator for MAPS’ Phase 2 trial of MDMA-assisted psychotherapy study in Boulder, Colorado, and currently in the MDMA Therapist Training Study. Additionally, she is a trainer for therapists working on MAPS’ upcoming Phase 3 studies for MDMA-assisted psychotherapy.

Bruce Poulter, R.N., M.P.H., has been interested and worked much of his career with people in altered states. He has worked extensively with people in chronic pain and was an intimate observer of the first government-approved MDMA-assisted psychotherapy study in Madrid, Spain, in 1999. He has offered harm reduction services through Zendo Project, was an investigator in the MAPS-sponsored Phase 2 MDMA/PTSD trial. and is currently an investigator in the MDMA Therapist Training Study. He ran for the U.S. Senate in 2002.

Sara Gael, M.A., received her Master’s degree in Transpersonal Counseling Psychology at Naropa University. She began working with MAPS in 2012, coordinating psychedelic harm reduction services at festivals and events worldwide with the Zendo Project. Sara was an Intern Therapist for the recently-completed MAPS-sponsored Phase 2 clinical trial of MDMA-assisted psychotherapy for PTSD in Boulder, CO. She maintains a private practice as a psychotherapist specializing in trauma and non-ordinary states of consciousness.

—

Purchase tickets: maps.org/boulder2018

Special thanks to members of our host committee (in formation): Sean Abraham and Jade Netanya Ullmann.

Questions? Contact [email protected]

A portion of ticket prices may be tax-deductible in the US. The fair market value of each ticket is $80.

—

About MAPS:

The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD.

�Learn about our research and other events at maps.org